Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ALGS - Aligos Therapeutics Inc


Previous close
13.16
0   0%

Share volume: 11,174
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$13.16
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
24%
Profitability 25%
Dept financing 10%
Liquidity 73%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
-8.32%
1 Month
-2.46%
3 Months
-15.47%
6 Months
-47.17%
1 Year
-42.05%
2 Year
-58.43%
Key data
Stock price
$13.16
P/E Ratio 
-12.86
DAY RANGE
N/A - N/A
EPS 
-$0.63
52 WEEK RANGE
$8.71 - $30.00
52 WEEK CHANGE
-$0.42
MARKET CAP 
973.954 M
YIELD 
N/A
SHARES OUTSTANDING 
76.810 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$27,882
AVERAGE 30 VOLUME 
$25,802
Company detail
CEO:
Region: US
Website: aligos.com
Employees: 85
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-㟠agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.

Recent news